Tivan Completes Scoping Study for Northern Territory Project; Shares Up 8%

-- Tivan (ASX:TVN) completed the scoping study for the Molyhil project in the Northern Territory, confirming that it is a low capital expenditure venture with relatively low technical risk, according to a Wednesday filing with the Australian bourse.

Findings showed that the high ore grade, particularly during the initial years of mining, will be further bolstered by molybdenum by-product credits, and minimal haulage requirements will keep logistics costs low, the filing said.

The company aims to advance the project towards a final investment decision in 2027, per the filing.

Shares rose 8% in afternoon trade on Wednesday.

BNP Paribas Adjusts Price Target on Ingersoll Rand to $82 From $94

Ingersoll Rand (IR) has an average rating of overweight and mean price target of $96.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $77.89, Change: $+0.43, Percent Change: +0.56%

$IR

Mizuho Adjusts Price Target on Humana to $290 From $258

Humana (HUM) has an average rating of hold and mean price target of $228.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $242.12, Change: $-1.00, Percent Change: -0.41%

$HUM

Jefferies Adjusts Price Target on Humana to $290 From $235

$HUM

Related Articles

BNP Paribas Adjusts Price Target on Ingersoll Rand to $82 From $94

Mizuho Adjusts Price Target on Humana to $290 From $258

Jefferies Adjusts Price Target on Humana to $290 From $235